'A joke, totally unacceptable': Zubiri slams COVID vaccine 50% efficacy rate

 By Deighton Acuin

Senate Majority Floor Leader Juan Miguel Zubiri (PHOTO: Philippine Information Agency)

"A joke, totally unacceptable." This were the remarks of Senate Majority Floor Leader Juan Miguel Zubiri on Friday in response over 50% efficacy rate of coronavirus vaccines.

This was after the Department of Science and Technology (DOST) said that 50% efficacy rate of Chinese pharmaceutical firm SinoVac's vaccine is 'acceptable' as one of the requirements of World Health Organization (WHO).

“That’s why the plan to get vaccines with only a 50% efficacy rate is totally unacceptable and a total waste of our funds and resources,” Zubiri said in a statement.

“Thats means there’s a 50/50 chance of you getting Covid even after being vaccinated is a joke… Totally unacceptable period!!” Zubiri added.

Zubiri said the government must consider the public safety and not its feelings to 'neighbor friends,' adding several factors such as pricing, practicality, efficacy, and safety.

"All these factors must be harmonized to make sure we deliver to our people the vaccine that is cost effective but is efficient and deliverable," the lawmaker said.

“We appeal to our Task Force leaders to look at the effectiveness of the vaccine rather than political or geo-political reasons."

“Safety of our people should come first, not the feelings of our neighboring friends,” the senator added.

Before the session adjournment amid holidays, the Senate Committee of the Whole constituted itself to keep an eye on government's vaccination program plans.

“The Senate will closely monitor the deals made through our oversight function and we have already constituted the Committee of the Whole to hear out the roll out plans on our government starting the 1st week of January,” Zubiri said.

“Hindi kami papayag na ibibigay sa ating mga kababayans yung mga bakunang palpak at walang silbi sa pag bigay proteksyon sa COVID-19,” he added.

RELATED ARTICLE: Philippine Daily Inquirer


Previous Post Next Post